Sanofi-Aventis Us LLC

Sanofi, Escherichia coli and vaccine

Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli.

Hosted on MSN · 14h

Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its

Reuters on MSN · 18h

J&J, Sanofi stop E.coli vaccine trial due to low effectiveness

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.

Seeking Alpha on MSN · 21h

Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.

policymed.com9d

Sanofi Sues HHS Over 340B Changes

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

moneycontrol.com6y

Sanofi Aventis

400 mg of Sanofi-Aventis US LLC." Govt to commission study on impact of FDI in pharma The government is likely to commission a study soon to assess the impact of foreign direct investment in ...

FiercePharma7d

Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

policymed.com10d

340B Compliance Battle: Sanofi Takes on HRSA and HHS

Recently, Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources… ...

Pharmabiz4h

Sanofi announces update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Sanofi announces update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study: Paris Friday, February 14, 2025, 12:00 Hrs [IST] A scheduled review of the E.mbrace p ...

pharmaphorum1y

Sanofi cuts price of Lantus insulin in US by 78%

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

Hosted on MSN14d

Sanofi stock price target raised to €120 by Leerink Partners

On Friday, Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares.

ETF Daily News4d

Yousif Capital Management LLC Purchases 20,690 Shares of Sanofi (NASDAQ:SNY)

DAVENPORT & Co LLC increased its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results